The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

In a report released today, James Quigley from Goldman Sachs maintained a Hold rating on Novartis AG (NOVN – Research Report), with a price ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Novartis has become the latest drugmaker to get in trouble over an employee’s LinkedIn likes. The U.K. | Novartis has become ...

Novartis chief executive says large pharma deals usually don't pay off. But the company remains interested in bolt-on ...

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...

While the political pushback to ESG continues to grow in the U.S., there was little sign in Davos last week that business ...

Novartis AG said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug, ...

Novartis AG's ( VTX:NOVN ) dividend will be increasing from last year's payment of the same period to $3.50 on 13th ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals ...

Deutsche Bank upgraded Novartis (NVS) to Buy from Hold with a price target of CHF 110, up from CHF 100. The firm says the company’s ...

Such companies can be wonderful options for income-seeking investments. If you're in the market for that combo, let's ...